Ilario Fulco1, Sylvie Miot1, Martin D Haug2, Andrea Barbero1, Anke Wixmerten1, Sandra Feliciano1, Francine Wolf1, Gernot Jundt3, Anna Marsano1, Jian Farhadi4, Michael Heberer1, Marcel Jakob1, Dirk J Schaefer1, Ivan Martin5. 1. Department of Surgery and Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland. 2. Department of Surgery and Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: martin.haug@usb.ch. 3. Institute of Pathology, University Hospital Basel, University of Basel, Basel, Switzerland. 4. Department of Plastic Surgery, Guy's and St Thomas' Hospital, London, UK. 5. Department of Surgery and Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: ivan.martin@usb.ch.
Abstract
BACKGROUND: Autologous native cartilage from the nasal septum, ear, or rib is the standard material for surgical reconstruction of the nasal alar lobule after two-layer excision of non-melanoma skin cancer. We assessed whether engineered autologous cartilage grafts allow safe and functional alar lobule restoration. METHODS: In a first-in-human trial, we recruited five patients at the University Hospital Basel (Basel, Switzerland). To be eligible, patients had to be aged at least 18 years and have a two-layer defect (≥50% size of alar subunit) after excision of non-melanoma skin cancer on the alar lobule. Chondrocytes (isolated from a 6 mm cartilage biopsy sample from the nasal septum harvested under local anaesthesia during collection of tumour biopsy sample) were expanded, seeded, and cultured with autologous serum onto collagen type I and type III membranes in the course of 4 weeks. The resulting engineered cartilage grafts (25 mm × 25 mm × 2 mm) were shaped intra-operatively and implanted after tumour excision under paramedian forehead or nasolabial flaps, as in standard reconstruction with native cartilage. During flap refinement after 6 months, we took biopsy samples of repair tissues and histologically analysed them. The primary outcomes were safety and feasibility of the procedure, assessed 12 months after reconstruction. At least 1 year after implantation, when reconstruction is typically stabilised, we assessed patient satisfaction and functional outcomes (alar cutaneous sensibility, structural stability, and respiratory flow rate). FINDINGS: Between Dec 13, 2010, and Feb 6, 2012, we enrolled two women and three men aged 76-88 years. All engineered grafts contained a mixed hyaline and fibrous cartilage matrix. 6 months after implantation, reconstructed tissues displayed fibromuscular fatty structures typical of the alar lobule. After 1 year, all patients were satisfied with the aesthetic and functional outcomes and no adverse events had been recorded. Cutaneous sensibility and structural stability of the reconstructed area were clinically satisfactory, with adequate respiratory function. INTERPRETATION: Autologous nasal cartilage tissues can be engineered and clinically used for functional restoration of alar lobules. Engineered cartilage should now be assessed for other challenging facial reconstructions. FUNDING: Foundation of the Department of Surgery, University Hospital Basel; and Krebsliga beider Basel.
BACKGROUND: Autologous native cartilage from the nasal septum, ear, or rib is the standard material for surgical reconstruction of the nasal alar lobule after two-layer excision of non-melanoma skin cancer. We assessed whether engineered autologous cartilage grafts allow safe and functional alar lobule restoration. METHODS: In a first-in-human trial, we recruited five patients at the University Hospital Basel (Basel, Switzerland). To be eligible, patients had to be aged at least 18 years and have a two-layer defect (≥50% size of alar subunit) after excision of non-melanoma skin cancer on the alar lobule. Chondrocytes (isolated from a 6 mm cartilage biopsy sample from the nasal septum harvested under local anaesthesia during collection of tumour biopsy sample) were expanded, seeded, and cultured with autologous serum onto collagen type I and type III membranes in the course of 4 weeks. The resulting engineered cartilage grafts (25 mm × 25 mm × 2 mm) were shaped intra-operatively and implanted after tumour excision under paramedian forehead or nasolabial flaps, as in standard reconstruction with native cartilage. During flap refinement after 6 months, we took biopsy samples of repair tissues and histologically analysed them. The primary outcomes were safety and feasibility of the procedure, assessed 12 months after reconstruction. At least 1 year after implantation, when reconstruction is typically stabilised, we assessed patient satisfaction and functional outcomes (alar cutaneous sensibility, structural stability, and respiratory flow rate). FINDINGS: Between Dec 13, 2010, and Feb 6, 2012, we enrolled two women and three men aged 76-88 years. All engineered grafts contained a mixed hyaline and fibrous cartilage matrix. 6 months after implantation, reconstructed tissues displayed fibromuscular fatty structures typical of the alar lobule. After 1 year, all patients were satisfied with the aesthetic and functional outcomes and no adverse events had been recorded. Cutaneous sensibility and structural stability of the reconstructed area were clinically satisfactory, with adequate respiratory function. INTERPRETATION: Autologous nasal cartilage tissues can be engineered and clinically used for functional restoration of alar lobules. Engineered cartilage should now be assessed for other challenging facial reconstructions. FUNDING: Foundation of the Department of Surgery, University Hospital Basel; and Krebsliga beider Basel.
Authors: Juan M Colazo; Brian C Evans; Angel F Farinas; Salam Al-Kassis; Craig L Duvall; Wesley P Thayer Journal: Tissue Eng Part B Rev Date: 2019-08 Impact factor: 6.389
Authors: Dafydd O Visscher; Hyeongjin Lee; Paul P M van Zuijlen; Marco N Helder; Anthony Atala; James J Yoo; Sang Jin Lee Journal: Acta Biomater Date: 2020-11-21 Impact factor: 8.947
Authors: M Caralt; J S Uzarski; S Iacob; K P Obergfell; N Berg; B M Bijonowski; K M Kiefer; H H Ward; A Wandinger-Ness; W M Miller; Z J Zhang; M M Abecassis; J A Wertheim Journal: Am J Transplant Date: 2014-11-17 Impact factor: 8.086
Authors: Irina Pomerantseva; David A Bichara; Alan Tseng; Michael J Cronce; Thomas M Cervantes; Anya M Kimura; Craig M Neville; Nick Roscioli; Joseph P Vacanti; Mark A Randolph; Cathryn A Sundback Journal: Tissue Eng Part A Date: 2015-12-15 Impact factor: 3.845
Authors: Anton Kushnaryov; Tomonoro Yamaguchi; Kristen K Briggs; Van W Wong; Marsha Reuther; Monica Neuman; Victor Lin; Robert L Sah; Koichi Masuda; Deborah Watson Journal: Adv Otolaryngol Date: 2014-07-23
Authors: Carlos M Chiesa-Estomba; Ana Aiastui; Iago González-Fernández; Raquel Hernáez-Moya; Claudia Rodiño; Alba Delgado; Juan P Garces; Jacobo Paredes-Puente; Javier Aldazabal; Xabier Altuna; Ander Izeta Journal: Tissue Eng Regen Med Date: 2021-04-17 Impact factor: 4.169